Leading the way
Sanford Burnham Prebys Medical Discovery Institute has deep expertise in fundamental biology and one of the most comprehensive drug discovery centers in the nonprofit world that accelerates the translation of our discoveries toward patient benefit.
of pioneering research
How we aim to improve human health
Sanford Burnham Prebys Medical Discovery Institute is dedicated to discovering the fundamental molecular causes of disease and devising the innovative therapies of tomorrow. The Institute takes a unique, collaborative approach to medical research and has established major research programs in cancer, neurodegeneration, diabetes, and infectious, inflammatory, and childhood diseases. The Institute is especially known for its world-class capabilities in stem cell research and drug discovery technologies.
Sanford Burnham Prebys is a U.S.-based, non-profit public benefit corporation based in San Diego (La Jolla), California.
Who we are
Sanford Burnham Prebys discoveries begin with our people – scientists, postdoctoral candidates, graduate students and support staff – who work collaboratively toward understanding the cause of disease and identifying new therapeutic approaches to improve human health.
As an independent, nonprofit institution, we focus on conducting biomedical research in cancer, neuroscience, immunolgy and rare children’s diseases.
The Institute is home to one of the most comprehensive drug discovery centers in the nonprofit world.
Our innovative approach to research underpins our strategic partnerships with the biotech and pharmaceutical industry.
We cultivate the next generation of biomedical scientists through our graduate and postdoctoral training programs.
Sanford Burnham Prebys employs more than 700 scientists and staff in San Diego (La Jolla), CA. We are widely recognized for our NCI-designated Cancer Center, the Conrad Prebys Center for Chemical Genomics and the Sanford Children’s Health Research Center.
Our approach to improving human health is built on three principles
Our track record of pioneering research spans more than 40 years, and has produced breakthrough discoveries in cancer, neuroscience, immunology and rare children's diseases.Learn More
We operate one of the most advanced drug discovery centers in the world that leverages biomedical discoveries to develop prototype drugs.Learn More
Education and training
We are committed to education and training the next generation of scientific leaders to ensure our legacy continues.Learn More
Farhy C, Hariharan S, Ylanko J, Orozco L, Zeng FY, Pass I, Ugarte F, Forsberg EC, Huang CT, Andrews DW, Terskikh AV
Elife 2019 Oct 22 ;8
Victorelli S, Lagnado A, Halim J, Moore W, Talbot D, Barrett K, Chapman J, Birch J, Ogrodnik M, Meves A, Pawlikowski JS, Jurk D, Adams PD, van Heemst D, Beekman M, Slagboom PE, Gunn DA, Passos JF
EMBO J 2019 Oct 21 ;:e101982
LPA<sub>1/3</sub> overactivation induces neonatal posthemorrhagic hydrocephalus through ependymal loss and ciliary dysfunction.
Lummis NC, Sánchez-Pavón P, Kennedy G, Frantz AJ, Kihara Y, Blaho VA, Chun J
Sci Adv 2019 Oct ;5(10):eaax2011
Cross Talk between eIF2α and eEF2 Phosphorylation Pathways Optimizes Translational Arrest in Response to Oxidative Stress.
Sanchez M, Lin Y, Yang CC, McQuary P, Rosa Campos A, Aza Blanc P, Wolf DA
iScience 2019 Sep 26 ;20:466-480
Madaro L, Torcinaro A, De Bardi M, Contino FF, Pelizzola M, Diaferia GR, Imeneo G, Bouchè M, Puri PL, De Santa F
PLoS Genet 2019 Oct 18 ;15(10):e1008408
Schroeder AM, Allahyari M, Vogler G, Missinato MA, Nielsen T, Yu MS, Theis JL, Larsen LA, Goyal P, Rosenfeld J, Nelson TJ, Olson TM, Colas AR, Grossfeld P, Bodmer R
Hum Mol Genet 2019 Oct 18 ;